Protocol Ledger

NCT04274049 · Phase III · COMPLETED

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

Interventional Phase III clinical trial protocol NCT04274049 sponsored by Beijing Northland Biotech. Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-28 Enrollment: 242 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04274049
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)242 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04274049
Protocol FieldVerified Registry Value
NCT IdentifierNCT04274049
Consolidated Lead SponsorBeijing Northland Biotech. Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment242 participants (ACTUAL)
Registered Start Date2019-08-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI